Mersana Therapeutics, Inc. (MRSN)

USD 1.69

(-16.75%)

Market Cap (In USD)

208.77 Million

Revenue (In USD)

36.85 Million

Net Income (In USD)

-171.67 Million

Avg. Volume

1.15 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.22-6.28
PE
-
EPS
-
Beta Value
1.475
ISIN
US59045L1061
CUSIP
59045L106
CIK
1442836
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Martin H. Huber M.D.
Employee Count
-
Website
https://www.mersana.com
Ipo Date
2017-06-28
Details
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.